CVM_OUT_1 [2025-04-04 17:53:43 -0400] 3136 Bytes | 827 tokens | Cum: 827 tkns (10.34% of 8k)
==========================================================================

We need a winner today and it's already 5:53:42 PM on Fri Apr 04, 2025 -0400 ... So let's find out if Cel-Sci (CVM) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 0.2297 up from 0.1989. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Cel-Sci (CVM)
IPO: 1991-10-10 (33 Years Ago)
Market Cap: $15,571,360
Shares Outstanding: 84,120,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XASE
Description: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Here’s the first list of news for Cel-Sci:

C1 - Mar-24-25 09:00AM - CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
C2 - Mar-18-25 04:05PM - CEL-SCI Announces Closing of $2.5 Million Offering
C3 - Mar-17-25 03:24PM - CEL-SCI Announces Pricing of $2.5 Million Offering
C4 - Mar-17-25 03:24PM 08:00AM - CEL-SCIs Head and Neck Cancer Registration Study Protocol Clears FDA Reviewin Talks with Potential Partners Interested in Commercialization of Multikine
C5 - Mar-14-25 08:30AM - Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCIs Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
C6 - Feb-20-25 08:00AM - CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
C7 - Feb-18-25 08:30AM - CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
C8 - Feb-14-25 04:24PM - Cel-Sci: Fiscal Q1 Earnings Snapshot

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Cel-Sci (CVM).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

CVM_OUT_3 [2025-04-04 17:53:48 -0400] 1099 Bytes | 269 tokens | Cum: 1099 tkns (13.74% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients**
Date: Mar-24-25 09:00AM
Source: (Business Wire)
URL: https://finance.yahoo.com/news/cel-sci-reports-data-treatment-130000249.html

Data published in peer-reviewed scientific journal Pathology and Oncology Research

Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration in ability to eat, drink, and swallow, ability for selfcare including walking and using the toilet, and improved emotional wellbeing

Complete responders to Multikine treatment reported a 100% (wherein all respondents scored the highest possible improvement from baseline) on 60% (39/65) quality of life measures

89.4% of partial responders to Multikine reported improved quality of life measures

Multi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CVM_OUT_5 [2025-04-04 17:53:49 -0400] 940 Bytes | 283 tokens | Cum: 1506 tkns (18.82% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-18T10:04:55Z - Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - AirNet Technology...
A2 - 2025-03-17T19:35:28Z - CEL-SCI announces pricing of $2.56M common stock offering...
A3 - 2025-03-17T19:45:01Z - CEL-SCI Corp (CVM) Prices 16M Share Offering...
A4 - 2025-03-17T12:11:28Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Annexon (NASDAQ:ANNX), Aclarion (NASDA...
A5 - 2025-03-17T12:21:32Z - CEL-SCI Corp's (CVM) Head and Neck Cancer Registration Study Protocol Clears FDA Review -- in Talks ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CVM_OUT_7 [2025-04-04 17:53:53 -0400] 1098 Bytes | 328 tokens | Cum: 1836 tkns (22.95% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - AirNet Technology (NASDAQ:ANTE), AGM Gr Hldgs (NASDAQ:AGMH)**Date: 2025-03-18Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44372194/why-harrow-shares-are-trading-higher-by-23-here-are-20-stocks-moving-premarketShares of Harrow, Inc. HROW rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial results and issued 2025 revenue guidance.

Harrow shares jumped 23.1% to $28.70 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers Regencell Bioscience Holdings Limited RGC gained 45.7% to $26.96 in pre-market trading after jumping over 46% on Monday. Bon Natural Life Limited BON rose 30.4% to $0.7985 in pre-market trading. Bon Nat

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CVM_OUT_9 [2025-04-04 17:53:54 -0400] 953 Bytes | 295 tokens | Cum: 2256 tkns (28.20% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-04T20:52:00Z - 3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference
B2 - 2023-12-04T18:10:23Z - Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B3 - 2023-07-18T17:00:51Z - Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B4 - 2023-07-18T13:51:42Z - US Stocks Mixed; Bank of America Tops Q2 Views
B5 - 2023-07-18T12:12:20Z - Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
B6 - 2023-05-02T12:08:44Z - Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CVM_OUT_11 [2025-04-04 17:53:58 -0400] 630 Bytes | 167 tokens | Cum: 2425 tkns (30.31% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/3-interesting-emerging-growth-stock-ideas-from-the-2024-think-equity-conference-200653751The article discusses three emerging growth stock ideas from the 2024 Think Equity Conference, including Cel-Sci, NetSol Technologies, and United States Antimony Corporation.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CVM_OUT_13 [2025-04-04 17:53:59 -0400] 1082 Bytes | 302 tokens | Cum: 2845 tkns (35.56% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-18 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 17, 2025, CEL-SCI Corporation, a Colorado corporation (the Company), entered into a Placement Agency Agrmt with ThinkEquity LLC (the Placement Agent) relating to the sale and issuance of 4,012,500 shares of the ...

S5 - 2025-02-14 10-Q PART I FIN INFO

Item 1.

Page

Condensed Balance Sheets at December 31, 2024 (unaudited) and September 30, 2024

Condensed Stmnts of Oper for the three months ended December 31, 2024 and 2023 (unaudited)

Condensed Stmnts of Stockholders Equity for...

S6 - 2025-01-13 10-K ITEM 7. MGT'S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion should be read in conjunction with the financial statements and the related notes thereto appearing elsewhere in this report.

Multikine (Leukocyte Interleuki...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CVM_OUT_15 [2025-04-04 17:54:04 -0400] 1098 Bytes | 307 tokens | Cum: 3154 tkns (39.42% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
PART I FINANCIAL INFORMATION

Item 1.

Page

Condensed Balance Sheets at December 31, 2024 (unaudited) and September 30, 2024

Condensed Statements of Operations for the three months ended December 31, 2024 and 2023 (unaudited)

Condensed Statements of Stockholders Equity for the three months ended December 31, 2024 and 2023 (unaudited)

Condensed Statements of Cash Flows for the three months ended December 31, 2024 and 2023 (unaudited)

Notes to Condensed Financial Statements (unaudited)

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3.

Quantitative and Qualitative Disclosures about Market Risks

Item 4.

Controls and Procedures

PART II

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Item 5.

Other Information

Item 6.

Exhibits

Signatures

2

CEL-SCI CORPORATION

CONDENSED BALANCE

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CVM_OUT_17 [2025-04-04 17:54:15 -0400] 5168 Bytes | 1449 tokens | Cum: 4768 tkns (59.60% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 1,682,359 | Perf Month: -36.72% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.33M | Perf Quarter: -47.92% | Short Float: 5.75% | ROE: -227.76% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.27 | Index: - | Short Ratio: 3.56 | ROI: -135.78% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 30.93 | Market Cap: 18.18M | Short Interest: 4.72M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.03 | Shs Outstand: 84.12M | Beta: 0.57 | EPS Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: -17.88% | Shs Float: 82.16M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -35.81% | Inst Own: 8.22% | Sales past 5Y: -15.85% | Earnings: Feb 18 BMO |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: -72.38% | Insider Own: 2.34% | Employees: - | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -9.47% | Insider Trans: 0.00% | Debt/Eq: 0.98 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: CEL SCI CORP (CVM) by KERSTEN GEERT R (Chief Executive Officer) on 2025-03-31
- Common Stock: 22786 shares at $0.2304 (D)

Inside Trans: CEL SCI CORP (CVM) by PRICHEP PATRICIA B (Chief Financial Officer) on 2025-03-31
- Common Stock: 15432 shares at $0.2304 (D)

Inside Trans: CEL SCI CORP (CVM) by TALOR EYAL (Chief Scientific Officer) on 2025-03-31
- Common Stock: 10416 shares at $0.2304 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -26920465.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.2161
Average Volume: 1827040.04
30-Day High: 0.3467
30-Day Low: 0.1989

[Detailed Financials: TTM 2024]
- Total Assets: $26,991,766.0
- Total Liabilities: $14,124,683.0
- Total Equity: $12,867,083.0
- Current Assets: $6,055,678.0
- Current Liabilities: $4,615,779.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $592,438

[Detailed Financials: FY 2024]
- Total Assets: $26,991,766.0
- Total Liabilities: $14,124,683.0
- Total Equity: $12,867,083.0
- Current Assets: $6,055,678.0
- Current Liabilities: $4,615,779.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $592,438
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

CVM_OUT_19 [2025-04-04 17:54:16 -0400] 1187 Bytes | 291 tokens | Cum: 5348 tkns (66.85% of 8k)
==========================================================================

Thanks for analyzing and reporting on Cel-Sci (CVM)
You did a great job!

Finally, I need your help with name/value pairs to increse the value of the report that will be programmatically processed.

Based only on the content you just analyzed during this conversation, please respond to these 9 follow-up questions.

This is the last thing you need to do. Please number each response from 1 to 9, one per line.
If you don’t know an answer, say “N/A” or “Unknown” — do not explain.

Questions:
1[] What tags best describe your prior report? (3–6 keywords, comma-separated)
2[] What is the primary market catalyst?
3[] Are there any secondary catalysts?
4[] What type of stock is this? (e.g., growth, value, turnaround, hype, squeeze)
5[] What is the dominant sentiment? (bullish, bearish, neutral, mixed)
6[] What upcoming event could impact this stock?
7[] Which article or SEC filing most influenced your analysis (by handle, e.g., A3, C2, S1)?
8[] Was any important information missing? If so, what?
9[] What additional information would have improved your analysis?

Return only:
1[biotech, fda-approval, momentum, etc.]
2[news of merger]
3[insider buying]
4[growth]

CVM_AI_21 [2025-04-04 17:54:16 -0400] 87 Bytes | 26 tokens | Cum: 5400 tkns (67.50% of 8k)
==========================================================================

5[bullish]
6[FDA approval announcement]
7[N/A]
8[No]
9[More detailed financial reports]